Daily Cardiology Research Analysis
Three impactful cardiology studies stood out: a large multicenter AI analysis that markedly improved mortality prediction by combining hybrid perfusion imaging and CT features; a meta-analysis of randomized trials showing intravascular imaging guidance reduces adverse events in CTO PCI; and a 10-year RCT follow-up indicating TiNO-coated stents lowered MACE versus everolimus-eluting stents in ACS. Together, they highlight progress in precision risk prediction and evidence-based interventional str
Summary
Three impactful cardiology studies stood out: a large multicenter AI analysis that markedly improved mortality prediction by combining hybrid perfusion imaging and CT features; a meta-analysis of randomized trials showing intravascular imaging guidance reduces adverse events in CTO PCI; and a 10-year RCT follow-up indicating TiNO-coated stents lowered MACE versus everolimus-eluting stents in ACS. Together, they highlight progress in precision risk prediction and evidence-based interventional strategies.
Research Themes
- AI-enabled multimodal risk stratification in cardiac imaging
- Imaging-guided optimization of complex PCI (CTO)
- Long-term safety and efficacy of stent platforms in ACS
Selected Articles
1. Holistic AI analysis of hybrid cardiac perfusion images for mortality prediction.
In 10,480 patients across four centers, a holistic AI model that combined CT attenuation correction radiomics, calcium, epicardial fat, perfusion, stress test, and clinical features achieved an AUC of 0.80 for all-cause mortality, outperforming calcium scoring or perfusion alone. Multi-organ, multi-feature integration significantly improved prognostic performance.
Impact: Demonstrates that routinely acquired CTAC contains rich prognostic information that, when integrated with MPI via AI, yields superior mortality prediction, potentially redefining risk stratification workflows.
Clinical Implications: Hybrid MPI protocols could incorporate automated AI extraction of CTAC radiomics and cardiac adiposity to provide decision-ready mortality risk scores, complementing traditional perfusion metrics.
Key Findings
- Multi-structure AI segmentation and radiomics from CTAC across 33 organs improved risk prediction.
- Integrated model (MPI + CT + stress + clinical) achieved AUC 0.80 for all-cause mortality.
- Model outperformed coronary calcium scoring (AUC 0.64) and perfusion alone (AUC 0.62), p<0.001.
Methodological Strengths
- Large multicenter cohort (n=10,480) with external heterogeneity across four sites
- Comprehensive multimodal feature integration and comparison against strong baselines
Limitations
- Retrospective design; potential confounding and dataset shift
- Clinical utility thresholds and prospective impact on decision-making not tested
Future Directions: Prospective, multi-center impact studies embedding AI risk scores into clinical workflows; exploration of causal links between specific CTAC radiomics and pathophysiology.
Low-dose computed tomography attenuation correction (CTAC) scans are used in hybrid myocardial perfusion imaging (MPI) for attenuation correction and coronary calcium scoring, and contain additional anatomic and pathologic information not utilized in clinical assessment. We seek to uncover the full potential of these scans utilizing a holistic artificial intelligence (AI) approach. A multi-structure model segmented 33 structures and quantified 15 radiomics features in each organ in 10,480 patients from 4 sites. Coronary calcium and epicardial fat measures were obtained from separate AI models. The area under the receiver-operating characteristic curves (AUC) for all-cause mortality prediction of the model utilizing MPI, CT, stress test, and clinical features was 0.80 (95% confidence interval [0.74-0.87]), which was higher than for coronary calcium (0.64 [0.57-0.71]) or perfusion (0.62 [0.55-0.70]), with p < 0.001 for both. A comprehensive multimodality approach can significantly improve mortality prediction compared to MPI information alone in patients undergoing hybrid MPI.
2. Intravascular Imaging Improves Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions: A Meta-Analysis of Randomized Controlled Trials.
Across five RCTs (n=1,296), IVI-guided CTO PCI significantly reduced MACE (RR 0.55) and TVR (RR 0.52) over 1–3 years versus angiography guidance, with consistent benefit in the IVUS subgroup. MI and death/cardiac death did not differ significantly.
Impact: Provides randomized evidence that intravascular imaging guidance improves hard outcomes in CTO interventions, supporting broader adoption of IVUS/OCT for complex PCI optimization.
Clinical Implications: Routine IVI guidance in CTO PCI can be justified to reduce repeat revascularization and composite adverse events; programs should ensure access to IVUS/OCT and operator proficiency.
Key Findings
- IVI-guided CTO PCI reduced MACE vs angiography guidance (7.2% vs 13%; RR 0.55; p=0.012).
- Target-vessel revascularization was lower with IVI (3.1% vs 6.7%; RR 0.52; p=0.038).
- Benefits were consistent in the IVUS subgroup (MACE RR 0.59; p=0.019); MI and mortality were similar.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials
- Trial sequential analysis reducing risk of type I error
Limitations
- Modest total sample size and 1–3 year follow-up window
- Heterogeneity in imaging modality (IVUS vs OCT) and procedural techniques
Future Directions: Head-to-head IVUS vs OCT trials in CTO PCI; cost-effectiveness analyses and implementation studies across diverse health systems.
Clinical data comparing intravascular imaging (IVI)-guided percutaneous coronary intervention (PCI) with angiography-guided PCI for chronic total occlusions (CTOs) are limited. This study aimed to compare clinical outcomes of IVI-guided versus angiography-guided PCI in patients with CTOs. A systematic review and meta-analysis were conducted to identify randomized controlled trials (RCTs) comparing IVI-guided with angiography-guided PCI in CTO populations. The primary endpoint was the incidence of major adverse cardiac events (MACE), a composite of death/cardiac death, myocardial infarction (MI), and target-vessel revascularization (TVR). Secondary outcomes included the individual components of MACE. A prespecified subgroup analysis was performed for intravascular ultrasound (IVUS) and optical coherence tomography (OCT). Five RCTs, including 1,296 patients, were analyzed, with 713 (55%) undergoing IVI-guided PCI. Over 1 to 3 years, MACE was significantly lower in the IVI-guided PCI group (7.2% vs 13%; relative risk [RR] 0.55; 95% confidence interval [CI] 0.35 to 0.88; p = 0.012; I² = 31%). In the secondary analysis, TVR incidence was lower in the IVI group (3.1% vs 6.7%; RR 0.52; 95% CI 0.29 to 0.97; p = 0.038). No statistical differences were observed for MI or death/cardiac death. In the IVUS subgroup, MACE was also lower in the IVI-guided PCI group (8.4% vs 14.3%; RR 0.59; 95% CI 0.37 to 0.91; p = 0.019). A trial sequential analysis suggested a low likelihood of type I error. In conclusion, IVI-guided PCI is associated with improved clinical outcomes compared with angiography-guided PCI for the treatment of CTOs.
3. 10-year follow-up of patients with titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome.
In the BASE-ACS randomized trial (n=827), TiNO-coated stents reduced 10-year MACE (HR 0.72), with fewer MI and definite stent thrombosis versus EES in ACS. Cardiac death and TLR trended lower with TiNO.
Impact: Rare 10-year randomized evidence comparing stent platforms in ACS, suggesting durable safety advantages of a polymer-free bioactive coating.
Clinical Implications: In ACS PCI, TiNO-coated stents may offer long-term reductions in MI and stent thrombosis; device selection and guideline updates should consider these data alongside contemporary DES evolution.
Key Findings
- TiNO reduced 10-year MACE vs EES (19.2% vs 28.3%; HR 0.72; p=0.04).
- Lower MI with TiNO (8.5% vs 13.9%; HR 0.59; p=0.02).
- Definite stent thrombosis lower with TiNO (1.8% vs 5.4%; HR 0.32; p=0.01).
Methodological Strengths
- Randomized controlled design with decade-long follow-up
- Hard clinical endpoints and time-to-event analyses
Limitations
- Single trial; device iterations and background therapy have evolved over time
- Non-significant trends for cardiac death and TLR may reflect limited power
Future Directions: Head-to-head trials versus latest-generation DES; pooled individual patient data meta-analyses and cost-effectiveness over long horizons.
OBJECTIVES: The aim of this study was to compare 10-year clinical outcomes of titanium-nitride-oxide-coated (TiNO)-stent versus permanent polymer everolimus-eluting (EES), for the primary endpoint of major adverse cardiac events (MACE) in patients with acute coronary syndrome (ACS). BACKGROUND: Previous trials with ACS patients have demonstrated non-inferiority of TiNO-stents compared with EES for clinical events up to 5-year follow-up. Long-term data from randomized clinical stent trials are scarce. METHODS: BASE-ACS trial randomized 827 ACS patients to receive either TiNO-stent or EES in a 1:1 fashion. The primary endpoint was MACE: a composite of cardiac death, non-fatal myocardial infarction (MI) or ischemia-driven target lesion revascularization (TLR). RESULTS: MACE was significantly lower in the TiNO group compared to EES group (19.2 % vs. 28.3 %; HR 0.72; CI 0.53-0.99; p = 0.04), driven mainly by reduction in MI (8.5 % vs. 13.9 %; HR 0.59; CI 0.37-0.93; p = 0.02) and cardiac death (3.4 % vs. 7.2 %; HR 0.55; CI 0.27-1.14; p = 0.09 (NS). The rate of TLR tended to be less frequent in the TiNO group (10.2 % vs. 15.1 %; HR 0.73; CI 0.48-1.12; p = 0.15 (NS). The rate of definite stent thrombosis was significantly less frequent in the TiNO group (1.8 % vs. 5.4 %; HR 0.32; CI 0.13-0.81; p = 0.01. CONCLUSIONS: At 10-year follow-up, the rate of MACE was significantly lower in ACS patients treated with TiNO-stents compared to patients treated with EES.